Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant Therapy
-
Published:2023-07
Issue:
Volume:
Page:
-
ISSN:2588-9311
-
Container-title:European Urology Oncology
-
language:en
-
Short-container-title:European Urology Oncology
Author:
Wu ZhenjieORCID, Chen Hui, Chen Qi, Ge Silun, Yu Nengwang, Campi Riccardo, Gómez Rivas Juan, Autorino Riccardo, Rouprêt Morgan, Psutka Sarah P., Mehrazin Reza, Porpiglia Francesco, Bensalah Karim, Black Peter C., Mir Maria C., Minervini Andrea, Djaladat Hooman, Margulis Vitaly, Bertolo Riccardo, Caliò Anna, Carbonara Umberto, Amparore Daniele, Borregales Leonardo D., Ciccarese Chiara, Diana Pietro, Erdem Selcuk, Marandino Laura, Marchioni Michele, Muselaers Constantijn H.J., Palumbo Carlotta, Pavan Nicola, Pecoraro Angela, Roussel Eduard, Warren Hannah, Pandolfo Savio Domenico, Chen Rui, Zhou Wenquan, Zhai Wei, He Miaoxia, Li Yaoming, Han Bo, Wan Jie, Zeng Xing, Yan Junan, Fu Yao, Ji Changwei, Fan Xiang, Zhang Guangyuan, Zhao Cheng, Jing Taile, Wang Anbang, Feng Chenchen, Zhao Hongwei, Sun Di, Wang Liang, Tai Sheng, Zhang Cheng, Chen Shaohao, Liu Yixun, Xu Zhipeng, Wang Haifeng, Gao Jinli, Wang Fubo, Cheng Jiwen, Miao He, Rao Qiu, Wang Jianning, Xu Ning, Wang Gongxian, Liang Chaozhao, Liu Zhiyu, Xia Dan, Jiang Jun, Zu Xiongbing, Chen Ming, Guo Hongqian, Qin Weijun, Wang Zhe, Xue Wei, Shi Benkang, Zhou Xiaojun, Wang Shaogang, Zheng Junhua, Ge Jingping, Feng Xiang, Li Minming, Chen Cheng, Qu Le, Wang Linhui
Subject
Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery
Reference37 articles.
1. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma;Choueiri;N Engl J Med,2021 2. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial;Powles;Lancet Oncol,2022 3. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial;Pal;Lancet,2022 4. The 2022 updated European Association of Urology guidelines on the use of adjuvant immune checkpoint inhibitor therapy for renal cell carcinoma;Bedke;Eur Urol,2023 5. Cost-effectiveness of adjuvant pembrolizumab after nephrectomy for high-risk renal cell carcinoma: insights for patient selection from a Markov model;Sharma;J Urol,2023
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|